View in EDS

Mass balance and absolute bioavailability of avenciguat (14C) after intravenous or oral administration in healthy male participants.

Saved in:
Bibliographic Details
Title: Mass balance and absolute bioavailability of avenciguat (14C) after intravenous or oral administration in healthy male participants.
Authors: Joseph D; Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA., Wong D; Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA., Mitra P; Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA., Auclair AM; Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA., Wolfgang T; Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA., Gao E; Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA., Herich L; Clinical Statistics, Staburo GmbH, München, Germany., Tiessen R; Clinical Research Physician, ICON plc (Formerly PRA Health Sciences), Groningen, The Netherlands.
Source: Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2026 Jan; Vol. 35 (1), pp. 75-84. Date of Electronic Publication: 2026 Jan 13.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9434197 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7658 (Electronic) Linking ISSN: 13543784 NLM ISO Abbreviation: Expert Opin Investig Drugs Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1744-7658
DOI:10.1080/13543784.2025.2612329